Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

NCT02581878 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer